To determine if Longboard Pharmaceuticals is still operating‚ several factors must be considered.
Table of contents
Recent Developments
Recent news indicates a significant development: Lundbeck’s acquisition of Longboard Pharmaceuticals. This acquisition was a strategic move to bolster Lundbeck’s neuroscience pipeline.
Acquisition Details
The acquisition was expected to be finalized in the fourth quarter of 2024‚ pending standard conditions like tender of shares and regulatory approvals.
Sale Announcement
Longboard Pharmaceuticals announced a 2.6 billion sale to Lundbeck. Cooley advised Longboard on this transaction.
Financial Reports
Longboard Pharmaceuticals released their third-quarter financial results for 2024‚ including corporate updates.
Corporate Updates
Longboard initiated the PACIFIC Study‚ evaluating LP352. LP659 IND submission was on track;
Given the acquisition by Lundbeck‚ Longboard Pharmaceuticals‚ as an independent entity‚ is no longer in business. It is now part of Lundbeck.
сегодня
Therefore‚ any ongoing research or development programs previously under Longboard’s banner are now integrated into Lundbeck’s operations. The specific fate of assets like LP352 and LP659 would depend on Lundbeck’s strategic decisions regarding their neuroscience pipeline.
Investors and stakeholders should now look to Lundbeck for information regarding these programs and any future developments stemming from Longboard’s previous research.
The acquisition marks a significant shift‚ with Longboard’s individual brand and identity likely being subsumed under Lundbeck’s corporate structure.
